Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-223575 in healthy subjects
NCT02155543Phase 1Completed
- Sponsor
- Allergan
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regorafenib in dry eye syndrome (DED), sponsored by Allergan. Started May 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02155543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155543.